SATURDAY, SEPTEMBER 17

6:30 p.m.-8:30 p.m.   Opening Keynote Session
Bayshore 1-3

Welcome Remarks

Session Chairpersons: Ernest T. Hawk, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven H. Itzkowitz, Mt. Sinai Hospital, New York, NY; Johanna W. Lampe, Fred Hutchinson Cancer Research Center, Seattle, WA

Recent advances in studying EGFR and its ligands in colorectal cancer
Robert J. Coffey, Jr., Vanderbilt University Medical Center, Nashville, TN

The discovery of the hereditary colorectal cancer genes: A historical perspective
C. Richard Boland, Jr., Baylor University Medical Center, Dallas, TX

8:30 p.m.-10:00 p.m.   Opening Reception
Bayshore 4-7

SUNDAY, SEPTEMBER 18

7:00 a.m.-8:00 a.m.   Continental Breakfast
Bayshore 4-7

8:00 a.m.-10:00 a.m.   Plenary Session 1: Understanding the Origins of Colorectal Neoplasia
Bayshore 1-3

Session Chairpersons: Kenneth W. Kinzler, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, and Barbara A. Leggett, Royal Brisbane Hospital, Brisbane, Queensland, Australia

8:00 a.m.-8:30 a.m.  Lessons from colorectal cancer
Kenneth W. Kinzler

8:30 a.m.-9:00 a.m.  The carcinogenic potential of bacterial biofilms
Cynthia L. Sears, Johns Hopkins University School of Medicine, Baltimore, MD

9:00 a.m.-9:30 a.m.  The serrated pathway of colorectal tumorigenesis
Barbara A. Leggett

9:30 a.m.-9:45 a.m.  Fusobacterium nucleatum and mutational landscape of colorectal cancer in whole-exome sequencing analysis*
Reiko Nishihara, Dana-Farber Cancer Institute, Boston, MA

9:30 a.m.-9:45 a.m.  Epigenetic and molecular drivers of inflammation-driven colorectal cancer*
Shariaz Baksh, University of Alberta, Edmonton, AB, Canada

*Short talks from proffered abstracts
CONFERENCE PROGRAM

10:00 a.m.-10:30 a.m.  Break
Galleria B

10:30 a.m.-12:30 p.m.  Plenary Session 2: High-Risk Cohorts and Genetic Susceptibility
Bayshore 1-3

Session Chairpersons: Steven H. Itzkowitz, Mount Sinai Hospital, New York, NY, and Roland P. Kuiper, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

10:30 a.m.-11:00 a.m.  Colorectal cancer in inflammatory bowel disease
Steven H. Itzkowitz

11:00 a.m.-11:30 a.m.  Germline next-generation sequencing panels for detection of inherited colorectal cancer syndromes
Matthew B. Yurgelun, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

11:30 a.m.-12:00 p.m.  Polyposis beyond FAP (and APC)
Roland P. Kuiper

12:00 p.m.-12:15 p.m.  The pig as a model for colorectal cancer*
Carolin Wander, Technische Universität München, München, Germany

12:15 p.m.-12:30 p.m.  Wnt and MAPK pathway activation in conventional and serrated colorectal neoplasia*
Vicki Whitehall, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

12:30 p.m.-3:00 p.m.  Free Time (Lunch on Own)

3:00 p.m.-5:00 p.m.  Plenary Session 3: Prevention
Bayshore 1-3

Session Chairpersons: Johanna W. Lampe, Fred Hutchinson Cancer Research Center, Seattle, WA, and Ernest T. Hawk, The University of Texas MD Anderson Cancer Center, Houston, TX

3:00 p.m.-3:30 p.m.  Realizing the promise of prevention (at the personal and population levels)
Ernest T. Hawk

3:30 p.m.-4:00 p.m.  Precision chemoprevention with aspirin
Andrew T. Chan, Massachusetts General Hospital, Boston, MA

4:00 p.m.-4:30 p.m.  Chemoprevention in hereditary GI cancer syndromes
Niloy Jewel Samadder, University of Utah Huntsman Cancer Institute, Salt Lake City, UT

4:30 p.m.-5:00 p.m.  Food and nutrition and colorectal cancer: Patterns for prevention
Johanna W. Lampe

5:00 p.m.-7:30 p.m.  Poster Session A and Reception
Bayshore 4-7

*Short talks from proffered abstracts

COLORECTAL CANCER: FROM INITIATION TO OUTCOMES
MONDAY, SEPTEMBER 19

7:00 a.m.-8:00 a.m.  Continental Breakfast
Bayshore 4-7

8:00 a.m.-10:00 a.m.  Plenary Session 4: Screening and Early Detection
Bayshore 1-3

Session Chairpersons: David A. Ahlquist, Mayo Clinic, Rochester, MN, and Steven H. Itzkowitz, Mount Sinai Hospital, New York, NY

8:00 a.m.-8:30 a.m.  Stool DNA detection of colorectal neoplasia
David A. Ahlquist

8:30 a.m.-9:00 a.m.  Decision analysis for colorectal cancer screening recommendations
Ann G. Zauber, Memorial Sloan Kettering Cancer Center, New York, NY

9:00 a.m.-9:30 a.m.  CT colonography in colorectal cancer screening
David H. Kim, University of Wisconsin School of Medicine and Public Health, Madison, WI

9:30 a.m.-9:45 a.m.  Using medical informatics to evaluate the risk of colorectal cancer in patients with clinically diagnosed sessile serrated polyps*
Andrea Burnett-Hartman, Institute for Health Research, Kaiser Permanente Colorado, Denver, CO

9:45 a.m.-10:00 a.m.  Interactions between nonsteroidal anti-inflammatory drugs and other risk factors on colorectal cancer risk*
Xiaoliang Wang, University of Washington, Seattle, WA

10:00 a.m.-10:30 a.m.  Break
Galleria B

10:30 a.m.-12:30 p.m.  Plenary Session 5: Molecular Diagnostics
Bayshore 1-3

Session Chairpersons: William M. Grady, Fred Hutchinson Cancer Research Center, Seattle, WA, and Kenneth W. Kinzler, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

10:30 a.m.-11:00 a.m.  Current and emerging molecular diagnostic assays for colorectal cancer
William M. Grady

11:00 a.m.-11:30 a.m.  Non-invasive detection of somatic mutations in the management of CRC
Nickolas Papadopoulos, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

11:30 a.m.-12:00 p.m.  Noncoding RNA biomarkers in gastrointestinal cancers
Ajay Goel, Baylor Research Institute, Dallas, TX

*Short talks from proffered abstracts
CONFERENCE PROGRAM

12:00 p.m.-12:15 p.m.  Complex sub-clonal populations in colorectal cancer lymph node metastasis*
  Karin M. Hardiman, University of Michigan, Ann Arbor, MI

12:15 p.m.-12:30 p.m.  The spectrum of somatic mutations in African American colorectal cancers*
  Nathan A. Ellis, University of Arizona Cancer Center, Tucson, AZ

12:30 p.m.-3:00 p.m.  Poster Session B and Lunch
  Bayshore 4-7

3:00 p.m.-5:00 p.m.  Plenary Session 6: Immunotherapy and Immune Cell Infiltration
  Bayshore 1-3
  
  **Session Chairpersons:** Stanley R. Hamilton, The University of Texas MD Anderson Cancer Center, Houston, TX, and Ernest T. Hawk, The University of Texas MD Anderson Cancer Center, Houston, TX

3:00 p.m.-3:30 p.m.  Immunocytes and prognosis of colorectal adenocarcinoma
  Stanley R. Hamilton

3:30 p.m.-4:00 p.m.  CRC immunotherapy: Trial updates
  Dung T. Le, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

4:00 p.m.-4:30 p.m.  The tumor microenvironment in colorectal cancer patients
  Robert A. Anders, Johns Hopkins University School of Medicine, Baltimore, MD

4:30 p.m.-4:45 p.m.  Targeting the MYC-WDR5 nexus in colorectal cancer*
  Audra M. Foshage, Vanderbilt University, Nashville, TN

5:00 p.m. - Evening on Own

TUESDAY, SEPTEMBER 20

7:00 a.m.-8:00 a.m.  Continental Breakfast
  Bayshore 4-7

8:00 a.m.-10:00 a.m.  Plenary Session 7: New Therapeutic Approaches for Colorectal Cancer
  Bayshore 1-3
  
  **Session Chairpersons:** Scott E. Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX, and Ernest T. Hawk, The University of Texas MD Anderson Cancer Center, Houston, TX

8:00 a.m.-8:30 a.m.  Clonal evolution and drug resistance in colorectal cancers: The EGFR-RAS signaling pathway
  Alberto Bardelli, University of Turino School of Medicine, Turino, Italy

*Short talks from proffered abstracts
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 a.m.-9:00 a.m.</td>
<td>Evolving targeting therapy for BRAF-mutated colorectal cancer</td>
</tr>
<tr>
<td></td>
<td>Scott E. Kopetz</td>
</tr>
<tr>
<td>9:00 a.m.-9:30 a.m.</td>
<td>Title to be announced</td>
</tr>
<tr>
<td></td>
<td>Josep Tabernero, Vall d'Hebron University Hospital, Barcelona, Spain</td>
</tr>
<tr>
<td>9:30 a.m.-10:00 a.m.</td>
<td>Therapies directed at the Wnt pathway</td>
</tr>
<tr>
<td></td>
<td>Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO</td>
</tr>
<tr>
<td>10:00 a.m.-10:15 a.m.</td>
<td>Break</td>
</tr>
<tr>
<td></td>
<td>Galleria B</td>
</tr>
<tr>
<td>10:15 a.m.-12:15 p.m.</td>
<td>Plenary Session 8: Outcomes, Survivorship, and Health Disparities</td>
</tr>
<tr>
<td></td>
<td>Bayshore 1-3</td>
</tr>
<tr>
<td></td>
<td><strong>Session Chairpersons:</strong> Polly A. Newcomb, Fred Hutchinson Cancer Research Center, Seattle, WA, and Johanna W. Lampe, Fred Hutchinson Cancer Research Center, Seattle, WA</td>
</tr>
<tr>
<td>10:15 a.m.-10:45 a.m.</td>
<td>Changes in diet and microbiome that mitigate CRC risk in Native Africans vs. African Americans</td>
</tr>
<tr>
<td></td>
<td>Stephen J. O'Keefe, University of Pittsburgh, Pittsburgh, PA</td>
</tr>
<tr>
<td>10:45 a.m.-11:15 a.m.</td>
<td>Understanding more about risk and prognostic factors: Lessons from the Colon Cancer Family Registry Polly A. Newcomb</td>
</tr>
<tr>
<td>11:15 a.m.-11:45 a.m.</td>
<td>Molecular pathological epidemiology of risk factors and CRC microbial and immune characteristics Shuji Ogino, Dana-Farber Cancer Institute, Boston, MA</td>
</tr>
<tr>
<td>11:45 a.m.-12:15 p.m.</td>
<td>Eliminating racial disparities in colorectal cancer Stephen Grubbs, American Society of Clinical Oncology, Alexandria, VA</td>
</tr>
<tr>
<td>12:15 p.m.</td>
<td>Departure</td>
</tr>
</tbody>
</table>